Cargando…
Combination of metformin and p38 MAPK inhibitor, SB203580, reduced myocardial ischemia/reperfusion injury in non-obese type 2 diabetic Goto-Kakizaki rats
Diabetic cardiomyopathy, especially myocardial ischemia reperfusion (I/R) injury, is a major cause of morbidity and mortality in type 2 diabetic patients. The increasing of basal p38 MAP Kinase (p38 MAPK) activation is a major factor that aggravates cardiac death on diabetic cardiomyopathy. In addit...
Autores principales: | Sanit, Jantira, Prompunt, Eakkapote, Adulyaritthikul, Punyanuch, Nokkaew, Nuttikarn, Mongkolpathumrat, Podsawee, Kongpol, Kantapich, Kijtawornrat, Anusak, Petchdee, Soontaree, Barrère-Lemaire, Stephanie, Kumphune, Sarawut |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676201/ https://www.ncbi.nlm.nih.gov/pubmed/31410128 http://dx.doi.org/10.3892/etm.2019.7763 |
Ejemplares similares
-
Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury
por: Mongkolpathumrat, Podsawee, et al.
Publicado: (2021) -
Endothelial-Cell-Derived Human Secretory Leukocyte Protease Inhibitor (SLPI) Protects Cardiomyocytes against Ischemia/Reperfusion Injury
por: Kongpol, Kantapich, et al.
Publicado: (2019) -
The cardioprotective effects of secretory leukocyte protease inhibitor against myocardial ischemia/reperfusion injury
por: Prompunt, Eakkapote, et al.
Publicado: (2018) -
Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion
por: Mongkolpathumrat, Podsawee, et al.
Publicado: (2022) -
Adeno-associated virus 9 vector-mediated cardiac-selective expression of human secretory leukocyte protease inhibitor attenuates myocardial ischemia/reperfusion injury
por: Mongkolpathumrat, Podsawee, et al.
Publicado: (2022)